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ABSTRACT	
	
The	identification	of	driver	mutations	is	fundamental	to	understanding	oncogenesis.	While	
genes	 frequently	mutated	 in	 B-cell	 lymphoma	 have	 been	 identified,	 the	 search	 for	 driver	
mutations	has	largely	focused	on	the	coding	genome.	Here	we	report	an	analysis	of	the	non-
coding	genome	using	whole	genome	sequencing	data	 from	117	B-cell	 lymphoma	patients.	
Using	promoter	capture	Hi-C	data	in	naïve	B-cells	we	define	cis-regulatory	elements,	which	
represent	 an	 enriched	 subset	 of	 the	 non-coding	 genome	 in	 which	 to	 search	 for	 driver	
mutations.	 We	 identify	 regulatory	 regions	 whose	 mutation	 significantly	 alters	 gene	
expression,	 including	 copy	 number	 variation	 at	 cis-regulatory	 elements	 targeting	 CD69,	
IGLL5	 and	MMP14,	 and	 single-nucleotide	 variants	 in	 a	 cis-regulatory	 element	 for	 TPRG1.	
Additionally,	we	 demonstrate	 the	 commonality	 of	 pathways	 targeted	 by	 coding	 and	 non-
coding	 mutations,	 exemplified	 by	 MMP14,	 which	 regulates	 Notch	 signaling,	 a	 pathway	
important	 in	 lymphomagenesis,	 and	whose	 expression	 is	 associated	with	 patient	 survival.	
This	study	provides	an	enhanced	understanding	of	lymphomagenesis	and	demonstrates	the	
advantages	 of	 employing	 chromosome	 conformation	 capture	 to	 decipher	 non-coding	
mutations	relevant	to	cancer	biology.	
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KEY	POINTS	
• Integration	of	B-cell	lymphoma	genomic	data	and	capture	Hi-C	reveals	recurrently	
mutated	regulatory	elements	influencing	gene	expression.		
• Expression	of	MMP14,	which	is	targeted	by	a	mutated	cis-regulatory	element,	is	
associated	with	B-cell	lymphoma	patient	survival.	
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INTRODUCTION	
	
B-cell	 lymphoma	 comprise	 a	 heterogeneous	 group	 of	 cancers,	 with	 diverse	 etiologies,	
clinical	behaviors	and	outcomes1.	The	different	B-cell	lymphoma	resemble	B	cells	at	specific	
stages	 of	 differentiation1,	 with	 diffuse	 large	 B-cell	 lymphoma	 (DLBCL)	 and	 follicular	
lymphoma	(FL),	accounting	for	around	43%	and	17%	of	cases	respectively2.		
	
The	 identification	 of	 driver	 mutations	 is	 fundamental	 to	 understanding	 oncogenesis	 and	
response	 to	 therapy.	 Although	 studies	 have	 identified	 genes	 and	 pathways	 frequently	
mutated	 in	B-cell	 lymphoma3-8,	many	tumors	have	no	detectable	driver	mutations	and	we	
do	 not	 yet	 have	 complete	 understanding	 of	 the	 genetic	 alterations	 necessary	 for	 tumor	
development6.		
	
The	search	for	driver	mutations	 in	B-cell	 lymphoma	has	however	been	primarily	restricted	
to	 coding	 regions3-6.	Gene	 regulation	 is	 highly	 cell-type	 specific,	 and	 the	 interpretation	 of	
mutations	within	non-coding	regions	of	lymphoma	genomes	has	been	in	part	constrained	by	
a	 lack	 of	 information	 on	 relevant	 regulatory	 elements	 and	 their	 target	 genes9,10.	
Furthermore,	although	mutation	recurrence	 is	an	 indicator	of	positive	selection	 in	tumors,	
the	 sheer	 size	 of	 the	 non-coding	 genome	places	 a	 high	 statistical	 burden	on	 an	 ability	 to	
distinguish	passenger	from	driver	mutations.		
	
Cis-regulatory	 elements	 (CREs)	 and	 promoters	 controlling	 gene	 expression	 represent	 a	
highly	 enriched	 subset	 of	 the	 non-coding	 genome	 in	which	 to	 search	 for	 potential	 driver	
mutations11.	 Herein	we	 have	 exploited	 this	 principle	 by	 using	 information	 from	promoter	
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capture	 Hi-C	 (CHi-C)	 in	 naïve	 B	 cells12	 in	 an	 analysis	 of	 whole-genome	 sequencing	 (WGS)	
data	on	80	DLBCL	and	37	FL	tumors.	By	linking	CRE	mutation	to	gene	expression	(Figure	1),	
we	 identify	 recurrently	 mutated	 non-coding	 regulatory	 regions,	 enhancing	 our	
understanding	 of	 the	 oncogenic	 pathways	 and	 mechanisms	 relevant	 to	 B-cell	 lymphoma	
biology.		 	 	
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METHODS	
	
Sequencing	data	
Data	from	40	DLBCL,	37	FL	and	61	chronic	lymphocytic	leukemia	(CLL)	tumors,	and	matched	
normal	 samples,	 were	 obtained	 from	 the	 International	 Cancer	 Genome	 Consortium	
(ICGC)5,13.	 Data	 from	 an	 additional	 40	 DLBCL	 tumors	 and	matched	 normal	 samples	 were	
obtained	 from	 The	 Cancer	 Genome	 Characterization	 Initiative	 (CGCI)8.	 The	 ICGC	 data	 has	
been	 aligned,	 processed	 and	 variants	 called	 as	 part	 of	 the	 Pan-Cancer	 Analysis	 of	Whole	
Genomes	 (PCAWG)	 project.	 A	 consensus	 approach	 to	 variant	 calling	 was	 adopted	 by	
PCAWG,	 combining	 the	 results	 of	 multiple	 pipelines	 to	 call	 SNVs,	 indels,	 CNVs	 and	 SVs	
(https://github.com/ICGC-TCGA-PanCancer).	 For	 each	 mutation	 type	 we	 downloaded	 and	
used	variants	called	by	a	respective	pipeline.	To	minimize	technical	differences	between	the	
cohorts,	we	aligned,	processed	and	called	variants	in	the	CGCI	data	using	identical	pipelines,	
as	 described	 in	 Supplementary	 Methods.	 RNA-sequencing	 data	 for	 all	 samples	 were	
obtained	from	the	CGCI	and	 ICGC	and	processed	as	described	 in	Supplementary	Methods.	
This	 study	 uses	 only	 published	 sequencing	 data	 and	 therefore	 ethical	 approval	 was	 not	
sought.		
	
Definition	of	regulatory	regions	
Promoter	 regions	 were	 defined	 as	 the	 intervals	 spanning	 400bp	 upstream	 to	 250bp	
downstream	of	transcription	start	sites	from	RefGene14.	CREs	were	defined	using	promoter	
CHi-C	 data	 generated	 on	 naïve	 B	 cells12.	 HindIII	 fragments	 interacting	 with	 at	 least	 one	
protein-coding	gene	promoter	were	considered	CREs.	Only	promoter-CRE	interactions	with	
a	CHiCAGO	score	≥515	and	a	linear	distance	≤5Mb16	were	included	in	the	analysis.	Additional	
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filtering	 the	 CHi-C	 data	 was	 completed	 to	 reduce	 false	 identification	 of	 interactions	
(Supplementary	Methods).		
	
Analysis	of	recurrent	mutation	of	regulatory	regions	
Promoters	and	CREs	were	tested	independently	for	recurrent	mutation	across	tumors	above	
that	expected	given	the	background	mutation	rates,	using	a	Poisson	binomial	model	as	per	
Melton	et	al.17.	We	employed	a	Poisson	binomial	model	as	it	allowed	us	to	consider	tumor-
specific	 mutation	 rates17,	 which	 is	 not	 possible	 using	 many	 alternative	 approaches18,19.	
Briefly,	the	mutation	probability	of	each	regulatory	region	in	each	tumor	was	computed	by	
fitting	 a	 logistic	 regression	model	 to	 all	 data,	 taking	 into	 account	 the	 following	 features:	
tumor	 ID,	mutation	 trinucleotide	 context,	 regional	 replication	 timing	and	1Mb	mutational	
density.	Replication	timing	was	estimated	as	the	mean	of	replication	timing	data	from	HeLa,	
HepG2,	K562,	MCF-7	and	SK-N-SH	cell	lines20.	Promoters	and	CREs	overlapping	open	reading	
frames	(defined	in	Ensembl	v73),	extended	5bp	in	each	direction	to	account	for	splice	sites,	
were	excluded	from	the	analysis18	Regions	of	CREs	overlapping	3’	UTR	and	5’	UTR	were	also	
excluded	from	the	analysis18.		
	
The	probability	that	a	region	is	mutated	was	defined	as:	
! region is mutated =  1−  (1−  !!)!!!! 	
where	i	is	the	base	position,	s	is	the	number	of	nucleotides	considered	in	the	region	(i.e.	not	
excluded)	and	pi	is	the	probability	that	a	mutation	occurs	at	base	i.	P-values	were	computed	
for	 each	 promoter	 and	 CRE	 using	 an	 approximation	 of	 the	 Poisson	 binomial	 model	
implemented	 in	 the	 poibin	 R-package17.	 Recurrent	 mutation	 P-values	 follow	 a	 discreet	
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distribution	and	we	 therefore	used	 the	 right	 tail	masses	 to	compute	 randomized	P-values	
for	each	region21.	
		
Relationship	between	simple	somatic	mutations	at	CREs	and	gene	expression	
Significantly	 mutated	 CREs	 were	 examined	 for	 differential	 expression	 of	 target	 genes	
between	mutated	and	non-mutated	tumors.	For	each	CRE,	tumors	were	classified	mutated	
or	 non-mutated	 based	 on	 the	 presence	 of	 SNVs	 or	 indels	 at	 the	 CRE,	 and	 differential	
expression	 assessed	 using	 permutation	 testing22.	 In	 the	 permutation	 testing	 a	 t-test	 was	
performed	using	 the	mutated/non-mutated	 tumor	 labels	 to	generate	a	 single	 t-value	 (the	
observed	 t-value).	The	expression	values	 for	 the	mutated/non-mutated	 tumors	were	 then	
permuted	 10,000	 times	 to	 generate	 10,000	 additional	 t-values	 (the	 permutated	 t-values).	
The	permuted	 t-values	generally	 fit	a	Gaussian	distribution,	against	which	 the	observed	 t-
value	could	be	compared	using	a	two-tailed	test22.	Samples	with	CNVs	at	either	the	CRE	or	
target	 gene	 were	 excluded.	 Additionally,	 samples	 with	 translocation	 or	 inversion	
breakpoints	≤1Mb	from	the	target	gene	were	excluded.	Only	CREs	mutated	in	at	 least	five	
tumors	 were	 tested,	 after	 removal	 of	 tumors	 with	 CNVs	 at	 the	 CRE	 or	 target	 gene,	 or	
proximal	 translocation	 or	 inversion	 breakpoints.	 CREs	 interacting	 with	 multiple	 gene	
promoters	were	tested	multiple	times.	Only	CREs	interacting	with	the	promoters	of	protein-
coding	 genes	were	 examined.	 The	 Benjamini-Hochberg	 procedure	was	 used	 to	 adjust	 for	
multiple	testing	and	significance	thresholded	at	Q<0.1.	
	
Relationship	between	CNVs	at	CREs	and	gene	expression	
Focal	amplifications	and	deletions	were	defined	as	absolute	copy	number	changes	≥1	and	
size	 ≤3Mb.	 To	 identify	 tumors	 with	 CNVs	 at	 CREs	 driving	 altered	 gene	 expression	 we	 (i)	
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identified	tumors	with	amplifications	or	deletions	at	a	CRE,	(ii)	excluded	tumors	with	CNVs	
at	the	target	gene,	 (iii)	excluded	tumors	with	translocation	or	 inversion	breakpoints	≤1Mb	
from	the	target	gene,	and	(iv)	assessed	the	association	between	the	copy	number	change	d	
and	log2-transformed	gene	expression	e	by	fitting	a	linear	regression	model:	! =  !! +  !!!.	
A	t-statistic	was	computed	using	the	estimated	!!	coefficient	and	standard	error,	and	a	P-
value	 was	 computed	 from	 this	 t-statistic	 under	 the	 null	 hypothesis	 of	 no	 association	
between	 copy	 number	 change	 and	 gene	 expression	 (!! = 0).	 Only	 regulatory	 regions	
mutated	 in	 at	 least	 five	 tumors	were	 tested,	 after	 exclusion	 of	 tumors	with	 CNVs	 at	 the	
target	 gene	 or	 proximal	 translocation	 and	 inversion	 breakpoints.	 Copy	 number	 changes	
were	 calculated	 relative	 to	 the	 ploidy	 of	 the	 tumor,	 as	 determined	 by	 ascatNgs23.	 For	
simplicity,	 all	 losses	 and	 gains	 were	 considered	 equally	 when	 calculating	 correlation	
coefficients	 (i.e.	each	 tumor	 is	defined	as	having	either	a	 loss,	no	change,	or	gain	 in	 copy	
number).	 In	 addition	 to	 conducting	 individual	 analyses	 of	 DLBCL	 and	 FL	 tumors,	 we	
completed	 a	 meta-analysis	 of	 the	 two	 tumor	 types	 under	 a	 fixed	 effects	 model.	 The	
Benjamini-Hochberg	 procedure	 was	 used	 to	 adjust	 for	 multiple	 testing	 and	 significance	
thresholded	at	Q<0.1.	
	
Survival	analysis	
To	examine	the	relationship	between	gene	expression	and	overall	survival,	we	made	use	of	
data	from	three	independent	DLBCL	patient	cohorts	from	Barrans	et	al.24,	Lenz	et	al.25	and	
Reddy	et	 al.6,	which	were	downloaded	 from	GEO.	Patients	were	 censored	based	on	 their	
last	 known	 clinical	 follow	 up.	 For	 each	 series,	 gene	 expression	 was	 first	 treated	 as	 a	
continuous	variable	in	a	Cox	proportional	hazards	model	with	inclusion	of	age	at	diagnosis,	
sex,	COO	and	treatment	received	(chemotherapy	or	rituximab-chemotherapy)	as	covariates.	
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Analysis	was	performed	using	the	log-rank	test	to	estimate	expression-associated	HRs,	and	
the	 Wald	 test	 was	 used	 to	 determine	 statistical	 significance.	 The	 proportional	 hazards	
assumption	in	the	Cox	models	was	assessed	using	scaled	Schoenfeld	residuals	implemented	
in	 the	 “cox.zph”	 function	 from	 the	 survival	 R-package.	Meta-analyses	 of	 the	 independent	
patient	cohorts	were	performed	under	a	fixed-effects	model.	We	also	stratified	cancers	by	
the	expression	of	the	gene,	defining	tumors	as	having	high	or	low	expression	of	a	gene	if	the	
expression	 value	 was	 within	 the	 top	 or	 bottom	 third	 of	 expression	 values	 for	 the	 gene	
across	all	cancers	respectively.	Kaplan-Meier	analysis	was	then	performed	using	this	tumor	
stratification	and	the	difference	between	the	survival	distributions	assessed	using	 the	 log-
rank	test.		
	
Data	availability		
ICGC	data,	processed	as	part	of	the	PCAWG	project,	were	downloaded	from	the	ICGC	Data	
Coordination	 Center	 (DCC)	 Data	 Portal	 (project	 codes	 MALY-DE	 and	 CLLE-ES).	 CGCI	 data	
were	downloaded	from	dbGaP	(phs000532.v7).	Naïve	B-cell	CHi-C	data	were	obtained	from	
Javierre	et	al12.	Histone	ChIP-seq	data	were	downloaded	from	BLUEPRINT	(sample	C005Q).	
Clinical	 and	 gene	 expression	 data	 used	 in	 survival	 analyses	 were	 downloaded	 from	 GEO	
(GSE32918	and	GSE10846)	and	obtained	from	Reddy	et	al6.	
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RESULTS	
	
Recurrently	mutated	non-coding	regulatory	regions	
After	 quality	 control	 and	 filtering	 of	WGS	 data,	we	 identified	 1,169,005	 single	 nucleotide	
variants	 (SNVs)	 in	 the	 DLBCL	 tumors	 (5.07	 mutations	 per	 megabase	 [Mb]),	 and	 255,889	
SNVs	 in	 FL	 tumors	 (2.40	mutations	 per	Mb;	Table	 S1).	 Recurrently	mutated	 regions	were	
identified	as	those	containing	a	greater	number	of	mutations	than	that	expected	given	the	
background	 mutation	 rate,	 adjusting	 for	 tumor-specific	 mutation	 rates,	 trinucleotide	
contexts,	replication	timing	and	1Mb	mutational	density17.	To	identify	somatic	mutations	in	
non-coding	regulatory	regions,	we	defined	21,750	regions	associated	with	17,677	genes	as	
promoters14.	We	identified	recurrently	mutated	promoters	associated	with	17	and	4	genes	
in	DLBCL	and	FL	tumors	respectively	 (Q<0.1,	Table	S2).	These	genes	 include	BLK,	 IRF8	and	
SPIB,	 which	 are	 implicated	 in	 lymphoma	 development	 and	 growth26-28,	 but	 for	 which	
recurrent	promoter	mutations	have	not	previously	been	reported9.		
	
Using	 promoter	 CHi-C	 in	 naïve	B	 cells12	we	defined	69,872	 genomic	 fragments	 containing	
putative	CREs	(median	size	2.1Kb),	 involved	in	142,791	unique	significant	 interactions	with	
promoters	 (median	 linear	 distance	 292Kb)	 and	 constituting	 7%	 of	 the	 genome.	 These	
promoter-interacting	 fragments	have	previously	been	 shown	 to	be	enriched	 for	ATAC-seq	
accessibility	 and	 regulatory	 histone	 marks12.	 We	 identified	 78	 recurrently	 mutated	 CREs	
interacting	 with	 the	 promoters	 of	 72	 genes	 in	 DLBCL	 tumors	 (Q<0.1,	 Table	 S3),	 and	 42	
recurrently	mutated	CREs	interacting	with	the	promoters	of	37	genes	in	FL	tumors	(Q<0.1,	
Table	S3).	The	majority	of	these	recurrently	mutated	CREs	(59%	in	DLBCL	and	63%	in	FL)	do	
not	 interact	with	the	promoter	of	the	closest	gene,	but	with	the	promoters	of	more	distal	
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genes.	Genes	targeted	by	recurrently	mutated	CREs	include	PAX5,	which	interacts	with	ten	
and	 eight	 recurrently	 mutated	 CRE	 fragments	 in	 DLBCL	 and	 FL	 respectively,	 and	 whose	
expression	 is	disrupted	by	non-coding	mutations	 in	chronic	 lymphoblastic	 leukemia	(CLL)13	
and	 multiple	 myeloma	 (MM)29.	 Furthermore,	 we	 identified	 recurrently	 mutated	 CREs	
interacting	with	genes	known	to	also	be	affected	by	coding	mutations,	including	five	genes	
previously	associated	with	non-coding	mutations	 in	B-cell	 lymphoma	(ARID5B,	BCL2,	BCL6,	
ETS1,	PAX5)	and	five	genes	for	which	only	coding	mutations	have	previously	been	reported	
(DMXL1,	IKZF3,	PCDHB1,	SEMA3D	and	SYPL1;	Table	S3)6,7,9,10.		
	
We	 used	 Palimpsest	 to	 characterise	 the	 processes	 most	 likely	 to	 be	 responsible	 for	 the	
recurrent	 mutation	 of	 promoters	 and	 CREs	 (Tables	 S4,	 S5	 and	 S6;	 Supplementary	
Methods)30-32.	 In	 DLBCL,	 promoters	 and	 CREs	 of	 genes	 including	 BCL6	were	 enriched	 for	
mutations	attributed	to	signatures	SBS84	or	SBS85	(P	<	0.05;	Table	S4),	which	are	associated	
with	 the	 activity	 of	 activation-induced	 deaminase	 (AID)32,	 supporting	 previous	
observations33.	Furthermore,	the	promoters	and	CREs	of	multiple	genes,	including	SGK1	and	
ST6GAL1	in	DLBCL,	were	enriched	for	mutations	attributed	to	signature	SBS3	(Table	S4	and	
S5),	 which	 is	 indicative	 of	 defective	 homologous	 recombination	 repair34,	 consistent	 with	
distinct	processes	underling	the	mutation	of	different	regulatory	elements.	
	
To	identify	non-coding	driver	mutations	in	regulatory	regions,	we	compared	the	expression	
levels	 of	 target	 genes	 of	 recurrently	 mutated	 CREs	 between	 mutated	 and	 non-mutated	
tumors,	 using	 RNAseq	 data	 from	 each	 tumor.	 Tumors	 with	 copy	 number	 changes	
overlapping	 either	 the	 CRE	 or	 target	 gene,	 and	 tumors	 with	 translocation	 or	 inversion	
breakpoints	≤1Mb	from	the	target	gene	were	excluded	from	this	analysis.	Mutation	of	a	CRE	
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interacting	with	 the	TPRG1	promoter,	occurring	 in	nine	 tumors	 (Figure	2),	was	associated	
with	 increased	 TPRG1	 expression	 in	 DLBCL	 (Q=0.09,	 Figure	 3,	 Table	 S7).	 This	 CRE	 is	
annotated	 by	 epigenetic	 marks	 indicative	 of	 active	 enhancers	 (Figure	 3,	 Figure	 S1,	
Supplementary	Methods)	and	located	at	a	regulatory	region	previously	identified	in	DLBCL	
to	 be	 bound	 by	 the	 bromodomain	 4	 (BRD4)	 chromatin	 reader	 protein	 (Figure	 3A,	
Supplementary	Methods)35,	which	is	characteristic	of	enhancers	important	in	DLBCL	growth	
and	cell	cycle	progression35.	Amplifications	of	the	TPRG1	gene	were	present	in	an	additional	
18	DLBCL	tumors,	with	the	mutation	of	 recurrently	mutated	TPRG1	CREs	and	TPRG1	gene	
amplifications	tending	to	occur	in	different	tumors	(P=0.016,	two-tailed	Fisher’s	exact	test),	
suggesting	alternative	mechanisms	of	gene	dysregulation.	Whilst	the	mutation	of	this	region	
has	 previously	 been	 reported	 in	 B-cell	 lymphoma,	 it	 was	 not	 previously	 associated	 with	
disrupted	 TPRG1	 expression9.	 This	 TPRG1	 CRE	 is	 enriched	 for	 mutations	 attributed	 to	
signatures	SBS84	(P=0.002)	and	SBS85	(P=0.030)	(Table	S5),	consistent	with	it	being	a	target	
of	AID	activity32,36.	Whilst	 the	 function	of	TPRG1	 is	poorly	characterized,	 it	 is	 regulated	by	
p6337,	which	has	been	implicated	as	playing	a	role	in	lymphoma	oncogenesis38.		
	
Copy	number	variation	at	CREs	dysregulates	gene	expression		
To	 identify	 CREs	 subject	 to	 somatic	 copy	 number	 variation	 (CNV),	 we	 identified	 CNVs	 in	
tumors	using	WGS	data	(Figure	2).	CNV-positive	CREs	were	assessed	for	a	correlation	with	
the	expression	of	target	genes,	excluding	cases	where	the	gene	was	encompassed	by	a	CNV,	
using	 RNAseq	 data	 from	 each	 tumor.	 In	 DLBCL	 tumors,	 20	 CNV-positive	 CREs	 were	
associated	with	target	gene	expression	(Q<0.1,	Table	S8),	19	of	which	are	located	in	a	220Kb	
region	on	chromosome	14.	In	FL	tumors,	two	CNV-positive	CREs,	located	in	the	same	region	
of	chromosome	14,	were	associated	with	target	gene	expression	(Q<0.1,	Table	S8).	
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The	 CD69	 promoter	 interacts	 with	 a	 CRE	 annotated	 by	 multiple	 epigenetic	 marks,	
overlapping	a	DLBCL	BRD4-bound	regulatory	region	(Figure	4A,	Figure	S2)35.	This	CRE	region	
is	 deleted	 in	 five	 DLBCL	 tumors,	 which	 were	 associated	 with	 higher	 CD69	 expression	
(Q=0.06,	 Figure	 4B,	 Table	 S8),	 suggesting	 this	 element	 acts	 as	 a	 repressor	 of	 CD69	
expression.	 CD69	 plays	 a	 role	 in	 B-cell	 development	 in	 mice39	 and	 enhanced	 antitumor	
immunity	has	been	observed	 in	mice	deficient	 in	CD6940.	Higher	CD69	protein	expression	
has	 previously	 been	 associated	 with	 shorter	 survival	 in	 B-cell	 lymphoma	 patients41,42,	
although	we	 did	 not	 replicate	 this	 association	with	 RNA	 expression	 in	 three	 independent	
series	 totaling	 1,670	 DLBCL	 cases	 (Table	 S9).	 Whilst	 deletion	 of	 the	 CD69	 CRE	 was	
accompanied	by	ETV6	exon	deletions	 in	 three	of	 the	 five	 tumors,	altered	ETV6	expression	
was	not	observed	in	these	samples	(Figure	4C).	
	
The	 T-cell	 receptor	 alpha	 (TRA)	 locus,	which	 undergoes	 V(D)J	 recombination	 during	 T-cell	
development43,	is	the	subject	of	copy	number	losses	and	gains	in	both	DLBCL	and	FL	tumors	
(Table	 S8).	 This	 region	 is	 annotated	with	multiple	 histone	marks	 and	 contains	 two	DLBCL	
BRD4-bound	regulatory	regions35	(Figure	5A,	Figure	S3).	 	 In	DLBCL,	eight	CRE	fragments	at	
the	TRA	locus	were	deleted	in	20	and	amplified	in	11	tumors.	These	CRE	fragments	contact	
the	promoters	of	 16	 genes,	with	 copy	number	 changes	 associated	with	 the	expression	of	
ABHD4,	LRP10,	MMP14,	PRMT5	and	SLC7A7	(Q<0.1,	Figure	5B-C,	Table	S8).	In	FL,	these	CRE	
fragments	 were	 deleted	 in	 17	 tumors	 and	 amplified	 in	 one,	 with	 copy	 number	 changes	
associated	 with	 the	 expression	 of	 only	 ACIN1	 (Q=0.04,	 Table	 S8).	 In	 the	 DLBCL	 tumors,	
increased	 CRE	 copy	 number	 was	 associated	 with	 reduced	 MMP14	 expression	 (Q=0.03,	
Figure	5B).	MMP14	 is	well	established	to	negatively	regulate	Notch	signaling44,	a	pathway	
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disrupted	in	DLBCL45,	and	through	which	the	loss	of	MMP14	impairs	B-cell	differentiation44.	
Lower	MMP14	expression	was	associated	with	worse	overall	survival	in	DLBCL	(hazard	ratio	
[HR]=0.85,	95%	confidence	interval	[CI]:	0.77-0.95,	P=0.003,	Figure	S4,	Table	S9).	Increased	
CRE	 copy	 number	 was	 associated	 with	 increased	 PRMT5	 expression	 in	 DLBCL	 tumors	
(Q=0.03),	 although	 this	 trend	 in	 expression	 was	 driven	 by	 lower	 PRMT5	 expression	 in	
tumors	with	CRE	deletions,	as	increased	PRMT5	expression	was	not	observed	in	tumors	with	
CRE	amplifications	(Figure	5C).		
	
Although	 copy	number	 changes	 at	 the	 TRA	 locus	have	previously	 been	observed	 in	B-cell	
malignancies46-48,	 it	 is	disputed	whether	 these	variants	are	pathogenic	 lesions	occurring	 in	
the	 tumor	cells46,	or	whether	 they	occur	not	 in	 the	 tumor	cells	but	 in	 infiltrating	T-cells47,	
which	are	often	found	in	 lymphoma	as	part	of	the	 immune	response49.	To	assess	whether	
infiltrating	T	cells	may	be	responsible	for	CNVs	at	the	TRA	locus,	we	addressed	the	potential	
issue	of	normal	contamination	using	tumor	purity	estimates	from	ascatNgs	for	each	sample.	
CNV	calling	by	ascatNgs	is	suboptimal	where	there	is	>50%	contamination50.	In	view	of	this,	
T-cell	 contamination	 is	 less	 likely	 to	 be	 responsible	 for	 observed	 CNVs	 when	 normal	
contamination	is	<50%.	In	15/20	of	DLBCL	samples	and	11/17	of	FL	samples	with	TRA	locus	
deletions,	normal	contamination	was	>50%,	suggesting	that	the	TRA	locus	 losses	observed	
in	these	samples	may	not	occur	in	cancer	cells,	but	instead	in	infiltrating	T-cells.	Conversely,	
in	 all	 11	 DLBCL	 samples	 and	 in	 the	 one	 FL	 sample	with	 TRA	 locus	 amplifications,	 normal	
contamination	 was	 <50%,	 consistent	 with	 TRA	 locus	 amplification	 being	 more	 likely	
associated	with	tumor	cells,	rather	than	infiltrating	cells.	
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Many	CREs	are	affected	by	expression-associated	CNVs	in	both	DLBCL	and	FL	tumors	(Table	
S8)	and	we	therefore	conducted	a	meta-analysis	of	these	association	statistics	under	a	fixed-
effects	 model	 (Table	 S10).	 In	 this	 meta-analysis,	 CNV-positive	 CREs	 interacting	 with	 the	
promoters	 of	MMP14,	 PRMT5	 and	 SLC7A7	were	 associated	with	 the	 expression	 of	 these	
genes	 (Q<0.1),	 suggesting	 a	 common	 effect	 of	 these	 CNVs	 on	 target	 gene	 expression	 in	
these	B-cell	malignancies.		
	
Meta-analysis	 of	 the	 DLBCL	 and	 FL	 tumors	 also	 identified	 two	 CREs	 interacting	 with	 the	
IGLL5	 promoter,	 for	 which	 focal	 deletion	 was	 associated	 with	 lower	 IGLL5	 expression	
(Q<0.1,	Table	S10).	The	CNV-positive	CRE	most	 strongly	association	with	 IGLL5	expression	
(Q=0.03,	Figure	6A-D)	was	deleted	in	14	DLBCL	tumors	and	6	FL	tumors,	and	annotated	by	
epigenetic	marks	indicative	of	active	enhancers	(Figure	6A,	Figure	S5).	Whilst	the	function	of	
IGLL5	remains	to	be	established,	it	is	recurrently	mutated	in	DLBCL51,	and	is	homologous	to	
IGLL1,	 a	 gene	which	plays	 a	 critical	 role	 in	B-cell	 development52.	 	 Furthermore,	 IGLL5	has	
been	shown	to	function	as	a	tumor	suppressor	in	a	CRISPR-based	screen	of	DLBCL	cell	lines6,	
a	 finding	 in	 keeping	 with	 reduced	 IGLL5	 expression	 being	 associated	 with	 CRE	 deletion.	
Although	 focal	 deletion	 of	 regions	 encompassing	 the	 IGLL5	 CRE	 occur	 in	 other	 B-cell	
malignancies,	 including	 childhood	 acute	 lymphoblastic	 leukemia	 (ALL)53	 and	 CLL54,	 their	
pathogenicity	 is	unclear54,55.	Since	the	 IGLL5	CRE	 is	 located	at	the	 immunoglobulin	 lambda	
light	chain	locus	(IGL)	Mraz	et	al.	postulated	that	such	deletions	are	likely	to	merely	be	the	
consequence	of	IGL	rearrangements55.	Conversely,	Mangum	et	al.	has	shown	that	the	locus	
deletions	observed	in	ALL	occur	independently	of	IGL	rearrangement	and	frequently	do	not	
involve	the	VJ	junction	nor	follow	the	ordered	model	of	V(D)J	recombination53.	Many	of	the	
CNVs	observed	in	the	DLBCL	and	FL	tumors	similarly	do	not	involve	the	VJ	junction	(Figure	
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6A),	suggesting	that	they	also	occur	independently	of	V(D)J	recombination.	As	focal	deletion	
of	this	region	has	previously	been	observed	in	CLL54,	we	completed	a	secondary	analysis	of	
this	CRE	 in	61	CLL	tumors13.	 In	 these	tumors	deletion	of	 the	CRE	was	also	associated	with	
lower	IGLL5	expression	(P=6.1×10-7,	Figure	6D),	suggesting	that	the	effect	of	the	deletion	of	
this	CRE	on	IGLL5	expression	may	be	generic	to	B-cell	malignancies.	
	
We	 examined	 whether	 tumors	 harboring	 CNV-positive	 CREs	 associated	 with	 target	 gene	
expression	 were	 enriched	 for	 DLBCL	 tumors	 of	 either	 the	 activated	 B-cell-like	 (ABC)	 or	
germinal	 center	B-cell-like	 (GCB)	 cell-of-origin	 (COO)	 subtypes	 (Table	 S11,	 Supplementary	
Methods).	 Although	CD69	CRE	deletions	were	observed	exclusively	 in	ABC	or	 unclassified	
tumors,	this	enrichment	was	non-significant	(P=0.16).		
	
Pathways	targeted	by	both	coding	and	non-coding	mutation	in	DLBCL	
To	 better	 inform	 the	 interplay	 between	 non-coding	 driver	mutations	 with	 other	 driver	
mechanisms,	 we	 identified	 pathways	 targeted	 by	 coding	 and	 non-coding	 mutations,	
combining	 genes	 identified	 in	 this	 analysis	 and	 genes	 with	 recurrent	 coding	mutations	
from	 an	 analysis	 of	 1,001	DLBCL	whole	 exomes6	 (Table	 S12,	Supplementary	Methods).	
One	pathway	identified	is	Notch	signaling	(Q=2.1×10-4),	which	contains	genes	affected	by	
coding	mutations,	such	as	CREBBP,	and	genes	affected	by	non-coding	mutations,	such	as	
IKZF1	 and	PLXND1.	 Other	 pathways	 affected	 by	 both	 coding	 and	 non-coding	mutations	
include	DNA	repair,	transcriptional	regulation	by	TP53,	and	WNT-signaling	(Q<0.1),	all	of	
which	are	linked	to	B-cell	lymphoma	development56.		
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DISCUSSION		
	
This	 analysis	 has	 identified	 putative	 non-coding	 driver	mutations	 in	 B-cell	 lymphoma	 and	
highlights	 that	 pathways	 key	 to	 lymphomagenesis	 can	 be	 targeted	 somatically	 through	
multiple	mechanisms.	Using	promoter	CHi-C,	we	identify	recurrently	mutated	CREs	and	link	
them	to	the	genes	they	regulate.	By	adopting	this	strategy	we	have	sought	to	address	the	
issue	that	many	recurrently	mutated	CREs	will	not	necessarily	interact	with	the	promoter	of	
the	proximal	gene	and	hence	the	target	gene	will	remain	unidentified.	This	is	illustrated	by	
the	CREs	interacting	with	the	promoters	of	IGLL5	and	TPRG1,	neither	of	which	interact	with	
their	proximal	genes,	but	whose	mutation	is	associated	with	dysregulated	expression	of	the	
respective	target	gene.	
	
It	 has	 previously	 been	 demonstrated	 that	 disruption	 of	 the	 Notch-signaling	 pathway,	
through	 coding	mutations	 in	 genes	 such	 as	NOTCH2	 and	 FBXW7,	 confers	 an	 unfavorable	
prognosis	in	DLBCL57.	Here	we	add	MMP14	to	the	list	of	genes	in	this	pathway	disrupted	in	
DLBCL,	the	lower	expression	of	which	is	similarly	associated	with	worse	survival	(Table	S9).		
	
V(D)J	 recombinase	 recognizes	 recombination	 sequence	 signals	 (RSSs),	 which	 consist	 of		
conserved	 heptamer	 and	 nonamer	 elements	 separated	 by	 a	 spacer58.	 We	 identified	 RSS	
sites	adjacent	to	the	boundaries	of	11/49	TRA	locus	CNVs,	10/25	 IGLL5	CRE	CNVs,	and	0/5	
CD69	CRE	CNVs	(Table	S13).	Calling	RSS	sites	is	inherently	difficult,	due	to	some	sites	being	
less	 conserved	 nor	 adjacent	 to	 identified	 breakpoints59.	 Therefore,	 whilst	 this	 analysis	
provides	 no	 evidence	 that	 many	 of	 the	 CRE-disrupting	 CNVs	 occur	 due	 to	 V(D)J	
recombination,	we	cannot	exclude	this	possibility.					
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Here	 we	 utilize	 naïve	 B-cell	 CHi-C	 data	 to	 characterize	 CREs	 and	 map	 them	 to	 their	
respective	 target	 genes.	 DLBCL	 and	 FL	 tumors	 develop	 from	 B	 cells	 at	 various	 stages	 of	
differentiation1,	 and	 naïve	 B-cell	 CHi-C	 data	 may	 therefore	 not	 fully	 recapitulate	 the	
regulatory	 interactions	 active	 in	 each	 tumors’	 COO.	 Nevertheless,	 many	 interactions	
involving	 mutated	 CREs	 associated	 with	 differential	 target	 gene	 expression	 are	 also	
observed	in	total	B-cell	CHi-C	data	(Table	S14)12,	suggesting	that	these	interactions	may	not	
be	 unique	 to	 a	 single	 stage	 of	 B-cell	 differentiation.	 These	 CREs	 are	 also	 annotated	 by	
epigenetic	marks	indicative	of	active	enhancers	in	B	cells	at	different	differentiation	stages	
(Figures	S1-S3	and	S5),	indicating	that	the	activity	of	these	CREs	is	not	restricted	to	a	single	
differentiation	stage.		
	
We	acknowledge	that	this	analysis	has	 limitations.	Firstly,	when	evaluating	the	effect	of	
CRE	mutations	on	gene	expression	we	consider	all	CRE	mutations	to	be	potential	drivers.	
It	 is	 also	 possible	 that	 some	 CREs	 contain	 a	 mixture	 of	 mutations	 that	 do	 and	 do	 not	
affect	gene	expression,	thereby	reducing	study	power.	Secondly,	we	do	not	consider	the	
clonality	 of	mutations	 in	 the	 differential	 expression	 analysis.	 Thirdly,	we	 did	 not	 assess	
whether	 CRE	 mutations	 affect	 promoter	 interactions	 or	 the	 affinity	 of	 transcription	
factors.	CRISPR/Cas9-based	genome	editing	and	electrophoretic	mobility	shift	assays	could	
be	used	to	investigate	the	functional	impact	of	these	mutations.		
	
In	summary,	our	findings	highlight	the	contribution	of	non-coding	mutations	and	CNVs	to	B-
cell	 lymphomagenesis,	 and	 provide	 further	 insight	 into	 the	 genetic	 complexity	 of	 B-cell	
lymphoma.	 Furthermore	 this	 study	 illustrates	 the	 advantages	 of	 using	 information	 from	
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chromosome	 conformation	 capture	 to	 decode	 regulatory	 elements	 relevant	 to	 B-cell	
lymphoma.		
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FIGURE	LEGENDS	
	
Figure	1:	Analysis	overview.	CGCI:	The	Cancer	Genome	Characterization	Initiative,	ICGC:	
The	International	Cancer	Genome	Consortium,	DLBCL:	diffuse	large	B-cell	lymphoma,	FL:	
follicular	lymphoma,	SNV:	single	nucleotide	variant,	CNV:	copy	number	variant,	CRE:	cis-
regulatory	element,	CHi-C:	capture	Hi-C.	
	
Figure	 2:	 Overview	 of	 CRE	mutations,	 amplifications	 and	 losses	 associated	with	 altered	
target	 gene	 expression	 in	 DLBCL	 and	 FL.	 Top	 panel	 shows	 the	 genome-wide	 mutation	
burden	for	each	tumor.	Second	panel	shows	the	occurrence	of	SNVs	in	the	TPRG1	CRE.	Third	
panel	 shows	 the	 occurrence	 of	 amplifications	 and	 losses	 at	 CREs	 associated	with	 altered	
target	 gene	 expression.	 Bottom	panel	 indicates	 the	 disease	 type	 and	 the	 cell	 of	 origin	 of	
each	tumor.	Figure	generated	using	GenVisR60.	
	
Figure	3:	Single	nucleotide	variants	at	cis-regulatory	element	are	associated	with	TPRG1	
expression	 in	 DLBCL.	 (A)	 SNVs	 at	 a	 CRE	 interacting	with	 the	TPRG1	promoter.	 Top	 panel	
shows	 position	 of	 SNVs	 at	 the	 CRE.	 Second	 panel	 shows	 chromatin	 looping	 interactions	
between	 the	TPRG1	promoter	 and	CREs,	with	 the	 interaction	 between	 the	 promoter	 and	
the	SNV-disrupted	CRE	colored	yellow.	Third	panel	details	ChIP-seq	histone	mark	signals	in	
naïve	B-cells.	Bottom	panels	show	positions	of	BRD4-bound	enhancers	 in	DLBCL35.	 (B)	CRE	
mutation	 status	 and	 gene	 expression.	 Whilst	 the	 TPRG1	 CRE	 is	 mutated	 in	 nine	 DLBCL	
tumors,	 only	 six	 tumors	 are	 considered	 in	 the	 differential	 expression	 analysis,	 as	 three	
tumors	have	CNVs	at	the	CRE	or	target	gene.	Differential	expression	assessed	using	t-value	
		 30	
permutation	test.	Boxplot	hinges	extend	to	the	most	extreme	data	points	that	are	no	more	
than	1.5	times	the	interquartile	range	from	the	box.		
	
Figure	 4:	 Copy	 number	 variation	 at	 cis-regulatory	 element	 is	 associated	 with	 CD69	
expression	in	DLBCL.	(A)	Loss	of	a	CRE	interacting	with	the	CD69	promoter.	Top	panel	shows	
position	of	CNVs	at	CRE,	all	of	which	are	copy	number	losses.	Second	panel	shows	chromatin	
looping	 interactions	between	 the	CD69	promoter	and	CREs,	with	 the	 interaction	between	
the	 promoter	 and	 the	 CNV-disrupted	 CRE	 colored	 yellow.	 Third	 panel	 details	 ChIP-seq	
histone	 mark	 signals	 in	 naïve	 B-cells.	 Bottom	 panel	 shows	 positions	 of	 BRD4-bound	
enhancers	in	DLBCL35.	(B)	CNV	status	at	CRE	and	CD69	expression	in	DLBCL	tumors.	(C)	CNV	
status	 at	 CRE	 and	 ETV6	 expression	 in	 DLBCL	 tumors.	 Association	 between	 copy	 number	
status	and	gene	expression	assessed	through	linear	regression.	Boxplot	hinges	extend	to	the	
most	extreme	data	points	that	are	no	more	than	1.5	times	the	interquartile	range	from	the	
box.	
	
Figure	5:	Copy	number	variation	at	cis-regulatory	elements	at	T-cell	receptor	alpha	locus	is	
associated	with	gene	expression	in	DLBCL.	 (A)	Gain	and	loss	of	a	CRE	interacting	with	the	
MMP14	and	PRMT5	promoters.	 Top	panel	 shows	position	 of	 CNVs	 at	 the	 CRE;	with	 copy	
number	gains	and	losses	represented	by	solid	and	dashed	lines	respectively.	Second	panel	
shows	 chromatin	 looping	 interactions	 between	 the	MMP14	 and	 PRMT5	 promoters	 and	
CREs,	with	the	interaction	between	the	promoters	and	the	considered	CRE	colored	yellow.	
Third	 panel	 details	 ChIP-seq	 histone	 mark	 signals	 in	 naïve	 B-cells.	 Bottom	 panels	 show	
positions	 of	 BRD4-bound	 enhancers	 in	 DLBCL4.	 CNV	 status	 at	 CRE	 and	 expression	 of	 (B)	
MMP14	and	 (C)	PRMT5	 in	 DLBCL	 tumors.	Whilst	 the	 CREs	 are	 lost	 in	 20	 tumors,	 only	 19	
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tumors	are	considered	in	the	differential	expression	analysis,	as	one	tumor	also	has	a	CNV	at	
the	 target	 genes.	Association	between	 copy	number	 status	 and	gene	expression	assessed	
through	linear	regression.	Boxplot	hinges	extend	to	the	most	extreme	data	points	that	are	
no	more	than	1.5	times	the	interquartile	range	from	the	box.	
	
Figure	 6:	 Copy	 number	 variation	 at	 cis-regulatory	 element	 is	 associated	 with	 IGLL5	
expression	in	B-cell	malignancies.	(A)	The	loss	of	a	CRE	interacting	with	the	IGLL5	promoter.	
Top	panel	shows	position	of	CNVs	at	the	CRE,	all	of	which	are	losses,	and	the	position	of	the	
VJ	 junction.	 Second	 panel	 shows	 chromatin	 looping	 interactions	 between	 the	 IGLL5	
promoter	 and	 CREs,	 with	 the	 interaction	 between	 the	 promoter	 and	 the	 considered	 CRE	
colored	 yellow.	 Third	 panel	 details	 ChIP-seq	histone	mark	 signals	 in	 naïve	B-cells.	 Bottom	
panels	shows	positions	of	BRD4-bound	enhancers	 in	DLBCL35.	CNV	status	at	CRE	and	gene	
expression	 in	 (B)	DLBCL	 and	 (C)	 FL	 tumors.	 (D)	CNV	 status	 at	CRE	and	gene	expression	 in	
secondary	 analysis	 of	 CLL	 tumors.	 Association	 between	 copy	 number	 status	 and	 gene	
expression	assessed	through	linear	regression.	Boxplot	hinges	extend	to	the	most	extreme	
data	points	that	are	no	more	than	1.5	times	the	interquartile	range	from	the	box.	
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SUPPLEMENTARY	METHODS	
	
Whole	genome	sequencing	data	
WGS	data	from	the	ICGC	samples	were	downloaded	from	the	ICGC	DCC	Data	Portal	
as	 tumor	 and	matched-normal	 BAM	 files	 aligned	 to	 GRCh37.	WGS	 data	 from	 the	
CGCI	 samples	 were	 downloaded	 from	 dbGaP	 as	 tumor	 and	 matched-normal	
unaligned	FASTQ	files.	We	aligned	CGCI	sample	reads	to	the	same	version	of	GRCh37	
employed	 in	 the	PCAWG	project,	using	BWA	MEM1.	Duplicate	 reads	were	marked,	
base	 quality	 scores	 recalibrated	 and	 local	 realignment	 around	 indels	 completed	
using	GATK	(v3)2.	
	
Calling	SNVs	and	indels	
For	 the	 ICGC	 samples,	 sets	 of	 SNVs,	 called	 using	 MuTect3	 with	 data	 from	 dbSNP	
v1324	 and	 COSMIC	 noncoding	 variants	 v545	 used	 for	 additional	 support,	 were	
downloaded	 from	 the	 ICGC	 DCC	 Data	 Portal.	 For	 the	 CGCI	 samples,	 we	 called	
mutations	across	the	whole	genome	using	MuTect	and	data	from	the	same	versions	
of	 dbSNP	 and	 COSMIC.	 For	 both	 the	 ICGC	 and	 CGCI	 samples	 we	 used	 FoxoG	 to	
remove	any	mutations	that	may	have	been	caused	by	oxidative	DNA	damage	during	
sample	 preparation6.	 In	 addition,	 we	 ensured	 that	 variants	 were	 supported	 by	 a	
minimum	of	one	alternative	read	in	each	strand	direction,	a	mean	Phred	base	quality	
score	>26,	mean	mapping	quality	≥50,	and	an	alignability	site	score	of	1	when	using	
the	alignability	of	100mers	by	GEM	from	ENCODE.	To	minimize	the	likelihood	of	false	
positives,	 the	 Duke	 excluded	 and	 HiSeqDepth	 top	 5%	 regions	 defined	 by	 UCSC	
Genome	 Browser	 were	 omitted	 from	 the	 analysis.	 Furthermore,	 we	 excluded	
immune	 system-coupled	 somatic	 hypermutation	 regions	 corresponding	 to	 429	
annotated	immunoglobulin	loci	and	the	major	histocompatibility	complex	loci	(with	
each	region	extended	by	50kb,	as	defined	in	Ensembl	v73).	
	
For	the	ICGC	samples,	small	insertions	and	deletions	(indels),	called	using	Platypus7,	
were	downloaded	from	the	ICGC	DCC	Data	Portal.	We	also	called	indels	for	the	CGCI	
samples	using	Platypus	with	default	parameters.		
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Calling	structural	variants	
For	 the	 ICGC	 samples,	 somatic	 CNVs	 called	 using	 ascatNgs8,	 and	 translocation	 and	
inversion	 breakpoints	 called	 using	 DELLY9,	 were	 downloaded	 from	 the	 ICGC	 DCC	
Data	Portal.	For	the	CGCI	samples,	we	also	called	somatic	CNVs	using	ascatNgs	and	
translocation	and	inversion	breakpoints	using	DELLY.			
	
RNA-sequencing	data	
ICGC	tumor	sample	RNA-seq	data	were	downloaded	as	aligned	BAM	files	 from	the	
ICGC	 DCC	 Data	 Portal.	 As	 part	 of	 the	 PCAWG	 project,	 reads	 in	 these	 files	 were	
aligned	to	GRCh37	using	TopHat210	and	GENCODE	v19	annotated	mRNA	transcripts.	
We	 downloaded	 CGCI	 tumor	 sample	 RNA-seq	 data	 as	 unaligned	 FASTQ	 files	 from	
dbGaP	 and	 aligned	 reads	 using	 a	 pipeline	 identical	 to	 that	 used	 to	 align	 the	 ICGC	
sample	reads.	For	both	the	ICGC	and	CGCI	samples,	we	computed	read	counts	using	
htseq-count	and	excluded	genes	with	zero	counts	 in	>90%	of	tumors11.	We	applied	
upper-quartile	normalization	and	computed	RPKM	values.	Batch	correction	between	
cohorts	was	 conducted	 using	 ComBat12.	 To	 avoid	 taking	 the	 logarithm	of	 negative	
values,	2	was	added	to	RPKM	values	before	they	were	log2	transformed.		
	
Classification	of	DLBCL	as	ABC	or	GCB		
DLBCL	tumors	were	assigned	to	ABC,	GCB	and	Unclassified	subtypes	as	per	Reddy	et	
al.13.	Using	this	approach,	32	DLBCL	tumors	were	classified	as	ABC,	39	as	GCB	and	9	
as	Unclassified.			
	
Additional	filtering	of	CHi-C	data	
We	performed	an	additional	filtering	of	the	CHi-C	data	to	remove	regions	identified	
as	duplicated	in	hg38,	but	not	hg1914,	as	these	may	lead	to	the	false	identification	of	
promoter-CRE	 interactions.	 To	 identify	 CREs	 not	 mapping	 to	 unique	 locations	 in	
hg38,	hg19	was	split	into	windows	of	100bp	prior	to	alignment	to	hg38	using	BWA.	
Bases	where	the	majority	of	reads	containing	 it	could	be	mapped	elsewhere	 in	the	
genome	 with	 at	 most	 one	 mismatch	 or	 gap	 were	 defined	 as	 poorly	 mapped	
(http://bit.ly/snpable).	 CREs	were	 excluded	 if	 >5%	 of	 their	 constituent	 bases	were	
poorly	mapped.		
	 3	
	
Mutational	signature	analysis	
Signatures	 reported	 by	 Alexandrov	 et	 al.15	were	 attributed	 to	 each	 sample	 using	
Palimpsest	with	default	parameters	(Table	S6)16,	17.	Only	those	signatures	previously	
observed	in	B-cell	lymphoma	and	lymphoid	cells	were	considered	(SBS1,	SBS2,	SBS3,	
SBS5,	SBS6,	SBS9,	SBS13,	SBS17a,	SBS17b,	SBS34,	SBS36,	SBS37,	SBS40,	SBS42,	SBS84	
and	SBS85)15.	Mutations	caused	by	canonical	activation-induced	cytidine	deaminase	
(AID)	 tend	 to	 cluster	 in	 the	 genome18,	 and	 we	 therefore	 classified	 mutations	 as	
clustered	 or	 non-clustered	 and	 attributed	 signatures	 to	 these	 mutations	
separately15.	Mutations	were	 classified	as	 clustered	 if	 the	minimum	distance	 to	all	
other	 mutations	 on	 the	 same	 chromosome	 in	 the	 same	 tumour	 was	 less	 than	
1,000bp18.	 The	numbers	 of	 clustered	 and	non-clustered	mutations	 associated	with	
each	 signature	 in	 each	 tumour	 was	 then	 summed	 to	 calculate	 the	 overall	
contribution	of	each	signature	to	each	tumour.	As	per	Letouzé	et	al.16,	we	computed	
the	 probability	 that	 each	 somatic	 mutation	 occurs	 as	 a	 result	 of	 the	 process	
underlying	 each	 mutational	 signature,	 considering	 the	 substitution	 type	 and	 the	
overall	 contribution	 of	 each	 signature	 to	 each	 tumour.	 To	 assess	 whether	 each	
recurrently	mutated	promoter	and	CRE	was	enriched	with	mutations	attributed	 to	
each	 signature,	 we	 compared	 the	 probability	 distribution	 of	 mutations	 in	 the	
regulatory	element	to	the	probability	distribution	of	all	other	mutations	observed	in	
tumours	in	which	the	regulatory	element	was	mutated,	using	a	one-sided	Wilcoxon	
rank-sum	 test.	We	 consider	 a	 significance	 threshold	 of	P<0.05	 to	 be	 suggestive	 of	
signature	enrichment.		
	
RSS	motif	identification	
We	used	FIMO	to	 identify	RSS	sites	at	CNV	boundaries19,	with	weights	 for	position	
weight	 matrices	 taken	 from	 a	 reported	 RSS	 conservation	 table20.	 For	 each	 CRE-
disrupting	CNV	associated	with	differential	gene	expression,	we	scanned	windows	of	
1kb	centered	on	each	CNV	boundary	called	by	ascatNgs,	to	allow	for	ambiguity	in	the	
exact	position	of	the	boundary.	Spacer	lengths	of	9-13bp	and	20-25bp	were	allowed	
between	the	motifs21.	In	Table	S13	we	report	those	RSS	sites	with	a	space	of	correct	
length	for	which	both	motifs	were	identified	by	FIMO	at	a	25%	FDR	threshold.		
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Subtype	analyses	
For	 those	 CREs	 affected	 by	 mutations	 associated	 with	 differential	 target	 gene	
expression,	 we	 assessed	 the	 enrichment	 of	 DLBCL	 COO	 subtypes	 in	 the	 affected	
tumors.	For	each	COO	subtype	enrichment	was	assessed	using	a	two-tailed	Fisher’s	
exact	test,	comparing	tumors	from	the	subtype	against	all	other	tumors.				
	
Integrated	analysis	of	coding	and	non-coding	mutations	
The	 tendency	 of	 coding	 and	 non-coding	 mutations	 affecting	 genes	 to	 occur	 in	
different	 tumors	 was	 assessed	 using	 a	 two-tailed	 Fisher’s	 exact	 test.	 Pathways	
significantly	 altered	 by	 coding	 and	 non-coding	mutations	 in	 DLBCL	were	 identified	
using	Reactome22,	with	significance	thresholded	at	Q<0.1.	150	genes	with	recurrent	
coding	mutations	in	DLBCL	identified	by	Reddy	et	al.	were	included	in	this	analysis13.		
	
Epigenetic	annotation	of	regulatory	regions		
ChIP-seq	data	 from	naïve	B	 cells	 (NC14_42),	 CD38-negative	naïve	B	 cells	 (S004KB),	
germinal	 center	 B	 cells	 (T14_10),	 unswitched	 memory	 B	 cells	 (pool_9)	 and	 class-
switched	memory	B	cells	 (csMBC_pool_2)	 for	H3K4me1,	H3K27me3,	H3K9me3	and	
H3K36me3	 were	 downloaded	 from	 BLUEPRINT.	 Co-ordinates	 were	 mapped	 from	
GRCh38	 to	GRCh37	using	 liftOver.	 BRD4-loaded	 enhancers,	 defined	using	 ChIP-seq	
data	 from	 the	 Ly1	 cell	 line,	were	 obtained	 from	 Chapuy	 et	 al.23,	 and	 co-ordinates	
mapped	from	NCBI36	to	GRCh37	using	liftOver.	
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Figure S1: SNVs at a CRE interacting with the TPRG1 promoter. Top panel shows position of the CRE. Second panel shows chromatin looping 
interactions between the TPRG1 promoter and CREs, with the interaction between the promoter and the SNV-disrupted CRE colored yellow. 
Lower panels detail ChIP-seq histone mark signals in B cells at different differentiation stages.
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Figure S2. Loss of a CRE interacting with the CD69 promoter. Top panel shows position of CNVs at the CRE, all of which are copy number 
losses. Second panel shows chromatin looping interactions between the CD69 promoter and CREs, with the interaction between the promoter 
and the CNV-disrupted CRE colored yellow. Lower panels detail ChIP-seq histone mark signals in B cells at different differentiation stages. 
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Figure S3. Gain and loss of a CRE interacting with the MMP14 and PRMT5 promoters. Top panel shows position of CNVs at the CRE; with 
copy number gains and losses represented by solid and dashed lines respectively. Second panel shows chromatin looping interactions between 
the MMP14 and PRMT5 promoters and CREs, with the interaction between the promoters and the considered CRE colored yellow. Lower 
panels detail ChIP-seq histone mark signals in B cells at different differentiation stages. 
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Figure S4. Kaplan-Meier survival analysis of (A) MMP14 and (B) PRMT5 expression (the two genes with expression significantly associated 
with survival in the Cox proportional hazards model analysis) in data sets from Barrans et al. (n=115), Lenz et al. (n=276) and Reddy et al. 
(n=404). Distribution differences assessed using the log-rank test. 
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Figure S5. Loss of a CRE interacting with the IGLL5 promoter. Top panel shows position of CNVs at the CRE, all of which are losses, and the 
position of the VJ junction. Second panel shows chromatin looping interactions between the IGLL5 promoter and CREs, with the interaction 
between the promoter and the considered CRE colored yellow. Lower panels detail ChIP-seq histone mark signals in B cells at different 
differentiation stages.
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